Cytek Biosciences vs 908 Devices
CTKB and MASS side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTKB and MASS compare
Cytek Biosciences is the larger company, worth 1.9 times as much as 908 Devices ($759M against $403M).
908 Devices grew revenue faster over the last twelve months (23.7% versus 5.5% for Cytek Biosciences).
908 Devices keeps more of each dollar of sales as profit, with a net margin of −36.9% compared with −39.1% at Cytek Biosciences.
908 Devices scores higher on the StockData Score (11 against 8 for Cytek Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTKB | MASS |
|---|---|---|
| Size and price | ||
| Market cap | $759M | $403M |
| Share price | $5.84 | $9.74 |
| Change, 1 year | 21.4% | 65.1% |
| Change, 5 years | −70.0% | −62.4% |
| Beta (5Y) | 1.10 | 1.70 |
| Employees | 702 | 172 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 1 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.7× (better) | 6.1× |
| P/B | 2.4× (better) | 2.7× |
| P/FCF | – | 153× |
| FCF yield | −1.8% | 0.65% (better) |
| Fair value | $6.36 | $7.62 |
| Margin of safety | 8.2% (better) | −27.8% |
| Growth | ||
| Revenue growth (TTM) | 5.5% | 23.7% (better) |
| Revenue growth, 5Y average | 209% (better) | 15.9% |
| Profitability | ||
| Gross margin | 54.7% (better) | 52.3% |
| Operating margin | −21.1% (better) | −42.7% |
| Net margin | −39.1% | −36.9% (better) |
| FCF margin | −6.5% | 4.0% (better) |
| Return on equity | −23.2% | −17.0% (better) |
| Return on invested capital | −12.8% (better) | −59.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −562.6× | – |
| Current ratio | 4.46 | 5.43 (better) |
| Altman Z-score | 4.15 (better) | 3.64 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.00% | – |
| Shareholder yield | −0.00% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 62.7% | 70.2% |
| Held by insiders | 10.6% | 21.0% |
| Insider net buying, 12 months | – | −$10.3M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.5% | 7.8% |
Go deeper
- CTKB stock overview
- CTKB income statement
- CTKB valuation and score
- MASS stock overview
- MASS income statement
- MASS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.